Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Effective date for benefit: April 1, 2026 Effective date for Prior Authorization: May 1, 2026
Call to action:Texas Children’s Health Plan (TCHP) would like to inform providers that Papzimeos (zopapogene imadenovec-drba) is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of adults with recurrent respiratory papillomatosis.
Background: Health and Human Services Commission (HHSC) will add Papzimeos (procedure code J3404) as a Medicaid and CHIP benefit beginning on April 1, 2026, and requires prior authorization for these programs effective May 1, 2026.
How this impacts providers: Authorization requirements
Prior authorization is required for Papzimeos (zopapogene imadenovec-drba).
The prior authorization request for Papzimeos (zopapogene imadenovec-drba) may be approved for 6 months for patients meeting the following requirements:
Patient is 18 years of age or older.
Patient has a confirmed diagnosis of recurrent respiratory papillomatosis (diagnosis code: D14.1).
Patient has documented human papillomavirus (HPV) serotype 6 or 11.
Prescribers must perform a surgical debulking of visible papilloma prior to the initiation of Papzimeos treatment (Day 1) to establish minimal residual disease.
Prescriber attests to remove visible papilloma prior to the third and fourth Papzimeos administration to maintain minimal residual disease during treatment.
Authorization will be approved for no more than one treatment course (i.e., four doses).
Monitoring parameters: Monitor for signs and symptoms of thrombotic events (e.g., shortness of breath, chest pain, leg swelling, persistent abdominal pain, neurological symptoms, including severe or persistent headaches or blurred vision).
Next step for Providers: Providers should share this communication with their staff.
